{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=naloxone",
    "query": {
      "intervention": "naloxone"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 606,
    "total_pages": 61,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=naloxone&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T02:00:43.148Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03976258",
      "title": "Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infection",
        "Opioid-use Disorder",
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "buprenorphine/naloxone",
          "type": "DRUG"
        },
        {
          "name": "Methadone",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone Injection",
          "type": "DRUG"
        },
        {
          "name": "Heroin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MetroHealth Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 190,
      "start_date": "2017-07-14",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-10-02",
      "last_synced_at": "2026-09-03T02:00:43.148Z",
      "location_count": 2,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03976258"
    },
    {
      "nct_id": "NCT01571362",
      "title": "A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Pain",
        "Low Back Pain",
        "Analgesia"
      ],
      "interventions": [
        {
          "name": "ALO-02",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 410,
      "start_date": "2012-06",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2017-04-04",
      "last_synced_at": "2026-09-03T02:00:43.148Z",
      "location_count": 52,
      "location_summary": "Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 38 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01571362"
    },
    {
      "nct_id": "NCT00591617",
      "title": "Optimizing Outcomes Using Suboxone for Opiate Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Opioid Dependency"
      ],
      "interventions": [
        {
          "name": "Psychosocial treatment plus Suboxone pharmacotherapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 202,
      "start_date": "2006-09",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-01-29",
      "last_synced_at": "2026-09-03T02:00:43.148Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00591617"
    },
    {
      "nct_id": "NCT04530591",
      "title": "User Acceptability of a Device-Based Opioid Overdose Intervention",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Opioid Overdose",
        "Opioid-use Disorder",
        "Substance Use Disorders"
      ],
      "interventions": [
        {
          "name": "Survey",
          "type": "OTHER"
        },
        {
          "name": "Interview",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2020-08-25",
      "completion_date": "2020-09-15",
      "has_results": true,
      "last_update_posted_date": "2021-07-07",
      "last_synced_at": "2026-09-03T02:00:43.148Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04530591"
    },
    {
      "nct_id": "NCT04817410",
      "title": "ED Initiated Oral Naltrexone for AUD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alcohol Use Disorder"
      ],
      "interventions": [
        {
          "name": "Emergency Department Initiated Oral Naltrexone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-09-28",
      "completion_date": "2023-11-02",
      "has_results": true,
      "last_update_posted_date": "2025-08-26",
      "last_synced_at": "2026-09-03T02:00:43.148Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04817410"
    },
    {
      "nct_id": "NCT03993392",
      "title": "SUBLOCADE Rapid Initiation Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Opioid-use Disorder"
      ],
      "interventions": [
        {
          "name": "TM buprenorphine",
          "type": "DRUG"
        },
        {
          "name": "SUBLOCADE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indivior Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2019-08-29",
      "completion_date": "2019-12-26",
      "has_results": true,
      "last_update_posted_date": "2025-03-25",
      "last_synced_at": "2026-09-03T02:00:43.148Z",
      "location_count": 1,
      "location_summary": "Berlin, New Jersey",
      "locations": [
        {
          "city": "Berlin",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03993392"
    },
    {
      "nct_id": "NCT05037032",
      "title": "Effects of Naltrexone on Nocturnal Breathing Patterns at Altitude",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Altitude",
        "Sleep Apnea, Central"
      ],
      "interventions": [
        {
          "name": "Naltrexone Pill",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Loma Linda Health Care System",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 16,
      "start_date": "2021-08-08",
      "completion_date": "2021-10-17",
      "has_results": false,
      "last_update_posted_date": "2023-04-26",
      "last_synced_at": "2026-09-03T02:00:43.148Z",
      "location_count": 1,
      "location_summary": "Loma Linda, California",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05037032"
    },
    {
      "nct_id": "NCT07022717",
      "title": "A Universal Primary Care Based Intervention to Reduce Youth Overdose Risk",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Overdose"
      ],
      "interventions": [
        {
          "name": "Brief youth overdose prevention education",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Information about Naloxone",
          "type": "OTHER"
        },
        {
          "name": "Usual standard of care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Boston Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2025-08-25",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-09-03T02:00:43.148Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07022717"
    },
    {
      "nct_id": "NCT01873729",
      "title": "An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Naltrexone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 3,
      "start_date": "2013-11",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2017-01-13",
      "last_synced_at": "2026-09-03T02:00:43.148Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01873729"
    },
    {
      "nct_id": "NCT01275599",
      "title": "Drug-Drug Interaction Study Between Telaprevir and Buprenorphine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis C",
        "Opioid-Related Disorders"
      ],
      "interventions": [
        {
          "name": "telaprevir",
          "type": "DRUG"
        },
        {
          "name": "buprenorphine/naloxone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 16,
      "start_date": "2011-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-06-08",
      "last_synced_at": "2026-09-03T02:00:43.148Z",
      "location_count": 2,
      "location_summary": "Overland Park, Kansas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01275599"
    }
  ]
}